In a proof-of-principle studypublished in Nature Nanotechnology, Dr. Matthias Stephan and other researchers at Fred Hutchinson Cancer Research Center showed that nanoparticle-programmed immune cells, known as T cells, can clear or slow the progression of leukemia in a preclinical model.
No comments:
Post a Comment